VIMPAT ORAL SOLUTION CV
Generic Name and Formulations:
Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL.
Indications for VIMPAT ORAL SOLUTION:
Monotherapy or as adjunct in partial-onset seizures in patients ≥4yrs.
See full labeling. Oral soln: use calibrated measuring device. Injection: may give without diluting, or mix in appropriate diluent and give by IV infusion preferably over 30–60 mins. For oral and injection: ≥17yrs: Monotherapy: initially 100mg twice daily (alternatively, may initiate with a 200mg single loading dose, followed 12hrs later by 200mg/day in 2 divided doses for 1 week); may increase at weekly intervals by 100mg/day in 2 divided doses. Maintenance dose: 300–400mg/day. Conversion from a single antiepileptic to lacosamide monotherapy: wait until the therapeutic dose is achieved and given for at least 3 days before withdrawing concomitant antiepileptic; should withdraw gradually over at least 6 weeks. Adjunct: initially 50mg twice daily (alternatively, may initiate with a 200mg single loading dose, followed 12hrs later by 200mg/day in 2 divided doses for 1 week); may increase at weekly intervals by 100mg/day in 2 divided doses. Maintenance dose: 200–400mg/day. Switching from oral to inj: give same initial dosing regimen as that used in orally administered. Severe renal impairment (CrCl<30mL/min), ESRD, mild-to-moderate hepatic impairment: reduce max dose by 25%; if concomitant strong CYP3A4/CYP2C9 inhibitors: may need dose reduction. Consider supplemental dose (up to 50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).
<4yrs or Injection: not established. Oral soln: use calibrated measuring device. 4–<17yrs: Monotherapy or adjunct (11–<30kg): initially 1mg/kg twice daily; may increase at weekly intervals by 2mg/kg/day in 2 divided doses; maintenance dose: 6–12mg/kg/day; (30–<50kg): initially 1mg/kg twice daily; may increase at weekly intervals by 2mg/kg/day in 2 divided doses; maintenance dose: 4–8mg/kg/day; (≥50kg): initially 50mg twice daily; may increase at weekly intervals by 100mg/day in 2 divided doses; maintenance dose: 300–400mg/day (monotherapy) or 200–400mg/day (adjunct). Severe renal impairment (CrCl<30mL/min), ESRD, mild-to-moderate hepatic impairment: reduce max dose by 25%; if concomitant strong CYP3A4/CYP2C9 inhibitors: may need dose reduction. Consider supplemental dose (up to 50%) after hemodialysis. Avoid abrupt cessation (withdraw over 1 week).
Severe hepatic impairment: not recommended. Increased risk of suicidal thinking and behavior; monitor for clinical worsening or unusual changes. Cardiac conduction disturbances (eg, marked 1st or 2nd degree AV block, sick sinus syndrome unless paced, sodium channelopathies) or severe cardiac disease (eg, myocardial ischemia, HF, structural heart disease); obtain ECG before therapy and after titration; monitor closely esp. with IV route. Diabetic neuropathy. Oral soln: phenylketonurics. Elderly. Pregnancy. Nursing mothers.
Caution with concomitant drugs that prolong PR interval. May be potentiated by strong CYP3A4/2C9 inhibitors in patients with renal or hepatic impairment (see Adults).
Sodium channel inactivator.
Dizziness, headache, diplopia, nausea, vomiting, fatigue, ataxia; PR interval prolongation, AV block, syncope; rare: DRESS/multiorgan hypersensitivity reaction (discontinue if occurs).
To enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry call (888) 233-2334.
Tabs—60; Oral soln—200mL, 465mL; Single-use vials (20mL)—10
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|